1. Home /
    2. Altai Protocol Library /
  2. New Indication: Tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer ( POSEIDON)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer ( POSEIDON)

New Indication: Tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer ( POSEIDON)
Study:
  • Phase III, randomized, three-arm, open-label study
  • Previously untreated mNSCLC
  • Arm A: (T+C+CT) Tremelimumab 75 mg plus durvalumab 1,500 mg and chemotherapy for up to four 21-day cycles, followed by durvalumab 1,500 mg once every 4 weeks, with one additional tremelimumab dose after chemotherapy at week 16/cycle 6 (fifth dose). (n=338) Arm B:(D+CT) Durvalumab 1,500 mg plus chemotherapy for up to four 21-day cycles, followed by durvalumab 1,500 mg once every 4 weeks (n=338) Arm C: (CT) chemotherapy for up to six 21-day cycles (n=337)
Efficacy:
  • mPFS: 6.2 vs. 4.8 mos, HR: 0.72, p=0.0003 and mOS: 14.0 vs. 11.7 mos, HR: 0.77, p=0.003 (T+D+CT vs. CT)
  • mPFS: 5.5 vs. 4.8 mos,HR: 0.74, p=0.009 and mOS: 13.3 vs. 11.7 mos, HR: 0.86, p=0.075 (D + CT vs. CT)
  • ORR: 38.8% vs. 41.5% vs. 24.4% (T+D+CT vs. D +CT vs. CT)
Safety:
  • Any grade AEs:anemia (43.6% vs. 36.5% vs. 43.5%); nausea (37.6% vs. 31.1% vs. 34.5%); neutropenia (29.1% vs. 22.2% vs. 22.5%)
  • Grade ≥3 AEs: anemia (17.3% vs. 5.3% vs. 20.4%); neutropenia (16.1% vs. 12.6% vs. 12.0%)
  • İrAes: hypothyroidi (8.2% vs. 8.0%)

JCO, 2022 Nov 3; JCO2200975

Johnson L.M et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study

https://doi.org/10.1200/JCO.22.00975

Reviewed by Elvin CHALABİYEV, MD on Jan 30, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More